RVAC Medicines Pte. Ltd., a Singapore-based messenger RNA (mRNA) technology platform company incubated by CBC Group, announced on Wednesday that it has dosed a participant in a phase one, first-in-human study assessing the company's mRNA-based COVID-19 vaccine candidate, RVM-V001.
The Phase 1 study, an open-label, dose escalation study, is intended to assess the safety and immunogenicity of RVM-V001 in around 54 healthy adults in Australia.
This study is part of a series of clinical trials intended to assess RVAC's range of COVID-19 vaccine candidates that include one against the ancestral strain, one against the Omicron strain and a bivalent vaccine candidate with components of both ancestral and Omicron strains.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine